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OBJECTIVE: This retrospective study examined both the
use of abciximab treatment and its impact on hospital
length of stay among angioplasty patients enrolled in
managed care organizations.
METHODS: Retrospective billing data was obtained for
a sample of 1847 angioplasty patients who were enrolled
in US managed care organizations. Multivariate analysis
was used to control for a wide range of factors (patient
demographics, comorbidities, admission and discharge
information, and hospital characteristics such as region
of the country, size, number of angioplasties performed
per year) that may influence a patient’s likelihood of re-
ceiving abciximab or impact their length of stay in the
hospital. Estimation was conducted via a two-stage sam-
ple selection model.
RESULTS: Patients in poorer health were more likely to
receive abciximab. After controlling for high-risk indica-
tions and selection bias, results indicate that in contrast
with studies involving other payers, women and minori-
ties enrolled in these managed care organizations had the
same access to abciximab as other members. Further-
more, results indicate that angioplasty patients who were
given abciximab had a significantly shorter length of stay
(0.59 fewer days  0.24 days) than those patients who
did not receive abciximab.
CONCLUSIONS: These findings indicate that there are
potential economic benefits for hospitals administering ab-
ciximab. Given that hospital length of stay has been found
to be one of the most important determinants of total
healthcare costs, the reduced length of stay found in this
study implies cost off-sets for patients receiving abciximab.
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OBJECTIVE: To determine the outcomes associated with
a falls risk-reduction program.
METHODS: Medical and pharmacy claims data for
33,208 Medicare supplemental insurance plan patients
 75 years of age were evaluated. Each patient’s individ-
ual diagnosis- and drug-related risk factors were analyzed,
and providers for those patients at greatest risk received a
patient-specific educational intervention. Intermediate out-
comes (the mean number of high-risk drugs and the total
number of drugs prescribed) were evaluated before and for
9 months post-intervention in a study population of 1818
patients.
RESULTS: Pre-intervention there was a trend of escalat-
ing drug use in this population. Post-intervention, there
was a reduction (p  0.01) in the mean number of drugs
(	0.61) and high-risk drugs (	0.49). A retrospective
comparison population of 2211 patients showed an in-
crease (p  0.01) in the mean number of drugs (2.2)
and high-risk drugs (0.77) prescribed over a similar
time interval. Regression to the mean and selective mor-
tality do not appear to account for the results observed.
Examining the medical and economic benefits resulting
from this reduction in drug use has proven to be prob-
lematic. Falls are poorly documented in claims data.
Consequences of falls (e.g. hip fracture) can be identified
through claims review, but the incidence of these conse-
quences is relatively low, and differentiation between ini-
tial and follow up care is difficult. Several comparison
populations were evaluated for use in outcomes assess-
ment, but each has significant limitations. Also, medical
and economic benefits from a risk-reduction program
would be expected to accrue over an extended period of
time.
CONCLUSION: The intervention impacted the interme-
diate outcomes, but barriers prohibited analysis of poten-
tial medical and economic benefits.
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OBJECTIVE: Although economic evaluations are increas-
ingly conducted on a multinational basis, the issue of how
to analyze and interpret multinational economic data has
received little attention. This research illustrates the use of
cluster analysis to investigate patterns in resource utiliza-
tion between different countries or centers, and examines
the use of multilevel modeling to explicitly detect a hierar-
chical structure to the data if one is present and to explore
the relationship between site and outcome.
METHODS: The cluster analysis and multilevel model-
ing using SPSS for Windows and MLn, were based upon
resource utilization data captured in a multinational
phase III randomized controlled trial of two alternative
drug treatments for rheumatoid arthritis. In this trial,
data (e.g., inpatient episodes, outpatient visits, therapeu-
tic procedures, diagnostic procedures, GP visits, physio-
therapy sessions) were collected for 374 patients over a
108-week period, enrolled at 56 centers in nine European
countries. Clustering was investigated employing various
linkage and distance measures, and parameters were esti-
mated for the multilevel model specified with countries as
level 3 units, centers as level 2 units, and patients as level
1 units.
RESULTS: A variety of clustering solutions were gener-
ated according to the resource category examined and
visually presented in dendrogramatic form and icicle
plots. Across all categories, the countries resolved into
